Turn Therapeutics names Redfield chief scientific officer, sets Stifel forum date
Former CDC director Robert Redfield joins Turn Therapeutics as CSO, and the company will present atopic dermatitis data at a Stifel investor forum on September 23, 2026.
Turn Therapeutics Inc. (Nasdaq: TTRX) announced on September 9, 2026 the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield served as the 18th Director of the U.S. Centers for Disease Control and Prevention.1 He served in that role from 2018 to 2021.1 He had earlier held senior positions at the University of Maryland School of Medicine, where he co-founded the Institute of Human Virology and served as Professor of Medicine and Chief of Infectious Diseases.1 He also spent approximately two decades in the U.S. Army Medical Corps conducting research at Walter Reed Army Medical Center before retiring as Colonel.1
At Turn Therapeutics, Dr. Redfield will contribute toward the scientific and clinical strategy for GX-03 across atopic dermatitis, onychomycosis, hidradenitis suppurativa, and potential additional indications.1 He will work closely with CEO Bradley Burnam and Stephen M. Hahn, M.D., the company's Executive Clinical and Regulatory Lead and former FDA Commissioner.1
The company said GX-03 is being evaluated in atopic dermatitis, a disease involving skin-barrier dysfunction, microbial imbalance, immune activation, and itch, with preclinical research showing effects on inflammatory mediators including IL-36 and IL-31, and recent interim data the company described as showing strong efficacy and safety profiles.1 GX-03 is also being developed for onychomycosis, a fungal nail disease, with plans to evaluate additional indications.1
Separately, in a September 10, 2026 press release, Turn Therapeutics said CEO Bradley Burnam and Stephen M. Hahn, M.D. will present at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026 at 1:30 PM ET.2 The presentation will cover the company's atopic dermatitis clinical program, including its pruritus-focused stage 2 enrichment strategy and findings across patient populations, including those with moderate-severe baseline pruritus and a cohort with lower EASI scores despite high investigator-assessed disease severity (IGA).2 A live webcast will be available on the company's investor site, with a replay posted for about six months afterward.2
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.